Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Increases and Seroprevalence by Type of Clinical Care—September 2021 to February 2022 DOI Creative Commons
Kristie E.N. Clarke, Yun Kim, Jefferson M. Jones

et al.

The Journal of Infectious Diseases, Journal Year: 2022, Volume and Issue: 227(3), P. 364 - 370

Published: Oct. 25, 2022

Abstract Background Trends in estimates of US pediatric SARS-CoV-2 infection-induced seroprevalence from commercial laboratory specimens may overrepresent children with frequent health care needs. We examined trends and compared by testing type diagnostic coding. Methods Cross-sectional convenience samples residual sera September 2021-February 2022 52 jurisdictions were assayed for antibodies; monthly calculated age group. Multivariate logistic analyses associated International Classification Diseases-Tenth Revision (ICD-10) codes orders indicating well-child other specimens. Results Infection-induced increased each group, 30% to 68% (1–4 years), 38% 77% (5–11 40% 74% (12–17 years). On multivariate analysis, patients ICD-10 seropositive more often than aged 1–17 years (adjusted prevalence ratio [aPR] 1.04; 95% confidence interval [CI], 1.02–1.07); 9–11 receiving standard lipid screening those tests (aPR, 1.05; CI, 1.02–1.08). Conclusions doubled among younger 12 between 2021 February 2022, 85% adolescents. Differences did not substantially impact estimates.

Language: Английский

Long COVID: major findings, mechanisms and recommendations DOI Open Access
Hannah Davis, Lisa McCorkell, Julia Moore Vogel

et al.

Nature Reviews Microbiology, Journal Year: 2023, Volume and Issue: 21(3), P. 133 - 146

Published: Jan. 13, 2023

Language: Английский

Citations

2751
Monkeypox: disease epidemiology, host immunity and clinical interventions DOI Open Access
Fok‐Moon Lum, Anthony Torres‐Ruesta, Matthew Zirui Tay

et al.

Nature reviews. Immunology, Journal Year: 2022, Volume and Issue: 22(10), P. 597 - 613

Published: Sept. 5, 2022

Language: Английский

Citations

393
The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID DOI Creative Commons
Jingwei Li, Yun Zhou, Jiechao Ma

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Nov. 1, 2023

Abstract There have been hundreds of millions cases coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome 2 (SARS-CoV-2). With the growing population recovered patients, it crucial to understand long-term consequences and management strategies. Although COVID-19 was initially considered an illness, recent evidence suggests that manifestations including but not limited those cardiovascular, respiratory, neuropsychiatric, gastrointestinal, reproductive, musculoskeletal systems may persist long after phase. These persistent manifestations, also referred as COVID, could impact all patients with across full spectrum illness severity. Herein, we comprehensively review current literature on highlighting its epidemiological understanding, vaccinations, organ-specific sequelae, pathophysiological mechanisms, multidisciplinary In addition, psychological psychosomatic factors underscored. Despite these findings diagnostic therapeutic strategies based previous experience pilot studies remain inadequate, well-designed clinical trials should be prioritized validate existing hypotheses. Thus, propose primary challenges concerning biological knowledge gaps efficient remedies well discuss corresponding recommendations.

Language: Английский

Citations

65
SARS-CoV-2-specific T cell memory with common TCRαβ motifs is established in unvaccinated children who seroconvert after infection DOI Creative Commons
Louise C. Rowntree, Thi H. O. Nguyen, Łukasz Kedzierski

et al.

Immunity, Journal Year: 2022, Volume and Issue: 55(7), P. 1299 - 1315.e4

Published: June 8, 2022

As the establishment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell memory in children remains largely unexplored, we recruited convalescent COVID-19 and adults to define their circulating SARS-CoV-2-specific CD4

Language: Английский

Citations

44
Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States—October 25, 2020–February 26, 2022 DOI Creative Commons
Ryan E. Wiegand, Yangyang Deng,

Xiaoyi Deng

et al.

The Lancet Regional Health - Americas, Journal Year: 2022, Volume and Issue: 18, P. 100403 - 100403

Published: Dec. 2, 2022

Sero-surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can reveal trends and differences in subgroups capture undetected or unreported infections that are not included case-based surveillance systems. Cross-sectional, convenience samples remnant sera from clinical laboratories 51 U.S. jurisdictions were assayed for infection-induced SARS-CoV-2 antibodies biweekly October 25, 2020, to July 11, 2021, monthly September 6, February 26, 2022. Test results analyzed infection-induced, nucleocapsid-protein seroprevalence using mixed effects models adjusted demographic variables assay type. Analyses 1,469,792 serum specimens revealed increased 8.0% (95% confidence interval (CI): 7.9%–8.1%) November 2020 58.2% (CI: 57.4%–58.9%) The ratio the change estimated reported case prevalence was 2.8 2.8–2.9) during winter 2020–2021, 2.3 2.0–2.5) summer 3.1 3.0–3.3) 2021–2022. Change ratios ranged 2.6 2.3–2.8) 3.5 3.3–3.7) by region Ratios suggest a high proportion detected periods transmission. largest increases coincided with spread B.1.1.529 (Omicron) variant accessibility home testing. varied season highest midwestern southern United States Our demonstrate counts did fully differing underlying infection rates value sero-surveillance understanding full burden infection. Levels antibody seroprevalence, particularly spikes transmission, important contextualize vaccine effectiveness data as susceptibility population changes. This work supported Centers Disease Control Prevention, Atlanta, Georgia.

Language: Английский

Citations

44
OMICRON: Virology, immunopathogenesis, and laboratory diagnosis DOI

Mahsa Bazargan,

Reza Elahi, Abdolreza Esmaeilzadeh

et al.

The Journal of Gene Medicine, Journal Year: 2022, Volume and Issue: 24(7)

Published: June 21, 2022

Since its emersion, coronavirus disease 2019 (COVID-19) has been a significant global dilemma. Several mutations in the severe acute respiratory virus (SARS-Co-2) genome given rise to different variants with various levels of transmissibility, severity and mortality. Up until November 2021, concern declared by World Health Organization were Alpha, Beta, Delta Gamma. then, novel variant named Omicron (B.1.1.529) developed. BA.1, BA.1.1, BA.2 BA.3 are four known subvariants Omicron. The involves new spike protein, most which receptor binding site, increase transmissibility decrease antibody vaccine response. Understanding virology is necessary for developing diagnostic therapeutic methods. Moreover, important issues, such as risk re-infection, response kinds vaccines, need booster dose increased infection pediatrics, be addressed. In this article, we provide an overview biological immunopathological properties subvariants, clinical signs symptoms, vaccines against Omicron, re-infection approaches specific challenges successful control management rapid spread variant.

Language: Английский

Citations

42
SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study DOI Open Access
Mikael Knip, Anna Parviainen, Maaret Turtinen

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2023, Volume and Issue: 11(4), P. 251 - 260

Published: March 21, 2023

Language: Английский

Citations

31
An Overview of the Use of Nanoparticles in Vaccine Development DOI Creative Commons
Daniel Lozano, Vicente Larraga, Maria Vallet‐Regí

et al.

Nanomaterials, Journal Year: 2023, Volume and Issue: 13(12), P. 1828 - 1828

Published: June 9, 2023

Vaccines represent one of the most significant advancements in public health since they prevented morbidity and mortality millions people every year. Conventionally, vaccine technology focused on either live attenuated or inactivated vaccines. However, application nanotechnology to development revolutionized field. Nanoparticles emerged both academia pharmaceutical industry as promising vectors develop future Regardless striking nanoparticles vaccines research variety conceptually structurally different formulations proposed, only a few them advanced clinical investigation usage clinic so far. This review covered some important developments applied technologies last years, focusing successful race for preparation lipid employed anti-SARS-CoV-2

Language: Английский

Citations

27
SARS-CoV-2 accessory proteins reveal distinct serological signatures in children DOI Creative Commons

Asmaa Hachim,

Haogao Gu,

Otared Kavian

et al.

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: May 26, 2022

Abstract The antibody response magnitude and kinetics may impact clinical severity, serological diagnosis long-term protection of COVID-19, which play a role in why children experience lower morbidity. We therefore tested samples from 122 Hong Kong with symptomatic ( n = 78) asymptomatic 44) SARS-CoV-2 infections up to 200 days post infection, relative 71 infected adults (symptomatic 61, 10), negative controls 48). assessed serum IgG antibodies 14-wide antigen panel structural accessory proteins by Luciferase Immuno-Precipitation System (LIPS) assay circulating cytokines. Infected have levels Spike, Membrane, ORF3a, ORF7a, ORF7b antibodies, comparable ORF8 elevated E-specific than adults. Combination two unique targets, ORF3d ORF8, can accurately discriminate infection children. Principal component analysis reveals distinct pediatric signatures, the highest contribution variance are responses non-structural ORF3d, NSP1, ORF3a ORF8. From diverse cytokines that modulate immune priming inflammation, IL-8, MCP-1 IL-6 correlate specificity severity. Antibodies internal become an important sero surveillance tool roll-out vaccines population.

Language: Английский

Citations

29
Serosurveillance among urban slum and non-slum population immunized with COVID-19 vaccines in Bangladesh DOI Creative Commons
Protim Sarker, Md. Ahsanul Haq,

Evana Akhtar

et al.

Epidemiology and Infection, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 34

Published: Jan. 5, 2024

An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the 'Save PDF' action button.

Language: Английский

Citations

6